OXERVATE

(Cenegermin-Bkbj)

ApprovedSmall molecule

DDompé Farmaceutici S.p.A

OXERVATE is one of 52 small molecule programs targeting Keratitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

KeratitisActive, not recruiting

GrowthActive, not recruiting

KeratitisApproved

Active, not recruiting

GrowthPreclinical

Active, not recruiting

Competition

Competitive Landscape

364 competitors in Growth

#DrugCompanyPhaseTrials

OXERVATE

DDompé Farmaceutici S.p.A

Approved

1 2

Genotropin

EMD Serono

Preclinical

35 3

Lovenox

Sanofi

Preclinical

2 4

Zyloprim

Alnylam Pharmaceuticals

Preclinical

1 5

Zolymbus

AbbVie

Preclinical

1 6

Aricept

Eisai

Preclinical

1 7

Somavaratan

Glucophage

2 9

Glucagon

XXeris Pharmaceuticals

Preclinical

1 10

Trental

VValidus Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Treatment1 trial

NGF Treatment for Patients With Neuropathic Corneal Pain

Withdrawn·TTufts Medical Center·Phase 1·NCT05700864

Keratitis1 trial

Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis

Completed·DDompé Farmaceutici S.p.A·Phase 4·NCT04485546·37 enrolled

Growth1 trial

Nerve Growth Factor for the Treatment of Cornea Disease

Completed·SStanford University··NCT04552730·5 enrolled

Regulatory

FDA Approval Timeline[4]

Aug 22, 2018

OXERVATE

BLA BLA761094

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Cenegermin-Bkbj. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cenegermin-Bkbj compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cenegermin-Bkbj. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761094). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Dompé Farmaceutici S.p.A company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: DDompé Farmaceutici S.p.A

OXERVATE

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Treatment1 trial

Keratitis1 trial

Growth1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News